Shengtai Pharmaceutical, a leading domestic producer of pharmaceutical-grade glucose in China, recently announced that the company has retained DME Capital LLC to expand its strategic investor relations program. DME Capital, LLC is a full-service investor relations firm, representing growth oriented companies to the investment community.
DME Capital’s investor relations services include financial community and media relations, editorial services and interactive communications, as well as administrative, consulting and advisory services.
“As we continue to grow our operations, we believe this is the right time to send our message to the investment community,” stated Mr. Qingtai Liu chief executive officer of Shengtai Pharmaceutical. “After careful consideration, DME Capital, with their established relationships among institutional investors, combined with their extensive databases and pro active investor relations program, is the perfect partner for Shengtai Pharmaceutical.”
For additional information regarding Shengtai Pharmaceutical, please visit www.shengtaipharmaceutical.com.
To learn more about DME Capital, LLC, please visit www.dmecapital.com.
Let us hear your thoughts below: